Capricor Therapeutics
Logotype for Capricor Therapeutics Inc

Capricor Therapeutics (CAPR) investor relations material

Capricor Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Capricor Therapeutics Inc
Q3 2026 earnings summary10 Nov, 2026

Executive summary

  • Deramiocel’s BLA remained under FDA review with a November 22, 2026 PDUFA date; the August amendment added 24-month HOPE-3 extension data and proposed an indication for upper-limb impairment in DMD patients older than 9.

  • The FDA advisory committee voted 3–9 against evidence for the cardiomyopathy indication; the vote did not address HOPE-3’s primary upper-limb endpoint or overall benefit-risk.

  • Quarter-end cash, cash equivalents, restricted cash and marketable securities totaled $198.5M, expected to fund operations for at least 12 months.

Financial highlights

  • Q3 2026 revenue was $0; operating expenses were $44.7M versus $26.3M in Q3 2025, including R&D expense of $29.6M and G&A of $15.1M.

  • Q3 net loss was $42.7M, or $0.73/share, versus $24.6M, or $0.54/share; 9M net loss was $117.3M, or $2.03/share, versus $74.9M, or $1.64/share.

  • 9M operating expenses were $124.4M versus $79.0M; operating cash use was $96.4M versus $46.2M. No revenue was recognized in 9M 2026 or 9M 2025.

Outlook and guidance

  • Existing liquidity was expected to fund operations for at least 12 months; spending and commercialization costs depend on FDA review, additional funding and the NS distribution arbitration outcome.

  • The San Diego facility’s first floor was ready for initial launch supply; cleanroom expansion and second-floor validation were targeted for H1 2027, with planned full capacity of 2,000–2,500 patients or up to 10,000 doses annually.

  • European and Japanese regulatory engagement began; next steps for younger DMD patients and Becker muscular dystrophy depend on the U.S. regulatory outcome.

  • Final Phase 1 StealthX vaccine results, including cellular immune-response data, were anticipated in H1 2027, subject to NIAID study finalization.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Capricor Therapeutics earnings date

Logotype for Capricor Therapeutics Inc
FDA announcement23 Nov, 2026
Capricor Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Capricor Therapeutics earnings date

Logotype for Capricor Therapeutics Inc
FDA announcement23 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.